Amplifying Fluorescent Polymer Detection of BW Agents

Information

  • Research Project
  • 6555378
  • ApplicationId
    6555378
  • Core Project Number
    R43AI052937
  • Full Project Number
    1R43AI052937-01
  • Serial Number
    52937
  • FOA Number
    RFA-AI-02-05
  • Sub Project Id
  • Project Start Date
    8/1/2002 - 22 years ago
  • Project End Date
    7/31/2003 - 21 years ago
  • Program Officer Name
    ZOU, LANLING
  • Budget Start Date
    8/1/2002 - 22 years ago
  • Budget End Date
    7/31/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/19/2002 - 22 years ago
Organizations

Amplifying Fluorescent Polymer Detection of BW Agents

DESCRIPTION (provided by applicant): Nomadics will adapt amplifying fluorescent polymer (AFP) technology to nucleic acid detection. AFPs are a class of polymers that amplify optical signatures resulting from FRET or fluorescence quenching events. Combining this inherent signal amplification with the specificity exhibited by nucleic acid recognition events will enable a new generation of nucleic acid sensors that do not rely on target amplification or catalyzed reporter deposition. This AFP-based technology should make a significant contribution to the adaptation of nucleic acid diagnostics towards the demands of field operations in reducing size, weight, and power consumption. This will make the technology suitable for use in countering bioterrorism. The research will focus on nanoparticle AFP detection systems, as the particle format offers a number of advantages in the adaptation of AFP technology to PCR-less molecular analyses-principally, the ability to harness 3-dimensional signal amplification in the solid particle while retaining an optically clear fluid matrix. Particle systems can also minimize background and increase sensitivity through single-particle analyses. Further, variations in the AFP composition allow us to tune the emission color of the bead; this, in turn, will enable multiplex analyses to screen for multiple agents. In Phase I, Nomadics will demonstrate APP nanoparticle technology for the detection of nucleic acids. This will require fabrication and characterization of AFP nanoparticles and the development of efficient coupling chemistries for the attachment of nucleic acid probes. This will enable hybridization studies to quantify the sensitivity and selectivity of APP nanoparticles. Experience in the handling and performance of AFP systems will enable design and fabrication of laboratory prototype systems. Studies will focus on anthrax. Synthesis and testing of a molecular beacon for a specific anthrax targets will only be performed in Phase II. Phase I will include selection of an appropriate anthrax target based on a complete literature search and design of a molecular beacon in silico. In order to test the concept using APP nanoparticles in Phase I, a probe that has already been designed, synthesized, and tested by Nomadics for another target will be used. The goal of Phase I will be to demonstrate highly specific nucleic acid detection in the low (<10) femtomole range.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    119941
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:119941\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NOMADICS, INC.
  • Organization Department
  • Organization DUNS
    879735579
  • Organization City
    STILLWATER
  • Organization State
    OK
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    740741508
  • Organization District
    UNITED STATES